Monthly Prescribing Reference

Intravesical Gemcitabine Releasing System Under Review for High-Risk NMIBC

Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...
Yahoo Finance

J&J obtains FDA approval for gemcitabine intravesical system

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...
Mirage News

MHRA Approves Gemcitabine System for Bladder Cancer

As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close ...
Yahoo Finance

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Business Insider

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder ...

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system Phase 1 results show a manageable safety ...
Business Insider

TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive ...

Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct. 22, 2023 /PRNewswire/ -- The Janssen ...

Intravesical CAR T therapy opens door to bladder-sparing cancer treatment

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have ...
ascopubs.org

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results

Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study Adults with Eastern Cooperative Oncology Group ...
Finanznachrichten

Johnson & Johnson: U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...
Finanznachrichten

Johnson & Johnson's INLEXZO (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this ...